Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

The Effect of Crizanlizumab on the Number of Days Requiring Opioid Use for Management of Pain Associated with Vaso-Occlusive Crises in Patients with Sickle Cell Disease: Results from the Sustain Trial

Wally R Smith, MD, Kenneth I. Ataga, MD, Santosh L. Saraf, MD, Olufolake A. Adisa, MDMSc, Miranda Bailey, Nicholas Ramscar, MBBS, Ashley Bonner, PhD, Stephen Brown, PhD, Laura Pastor, MSc

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140428

Published: 2020

Journal Articles

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Elliott Vichinsky, MD, Victor R. Gordeuk, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD FAAP, Margaret Tonda, PharmD, Sarah Gray, PhD, Irene Agodoa, MD, Kenneth I. Ataga, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140863

Published: 2020

Journal Articles

An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)

Kenneth W. Wood, PhD, James Geib, BS, Eric Wu, PhD, Jason Berlin, MS, Irena Webster, MPH, MA, Kenneth I. Ataga, MD, Jo Howard, MBBChir, MRCP, FRCPath, Jeremie H. Estepp, MD, Marilyn J. Telen, MD, Julie Brevard, MPH

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-134266

Published: 2020

Journal Articles

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Jo Howard, MBBChir, MRCP, FRCPath, Kenneth I. Ataga, MD, R. Clark Brown, MD PhD, Maureen Achebe, MD MPH, Videlis Nduba, MD, Amal El-Beshlawy, MD, Hoda Hassab, MD, Irene Agodoa, MD, Margaret Tonda, PharmD, Sarah Gray, PhD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Elliott Vichinsky, MD

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-140553

Published: 2020

Journal Articles

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Laurie DeBonnett, MD, Jeremie Lincy, Julie Kanter, MD

Blood (2019) 134 (Supplement_1): 2289.

https://doi.org/10.1182/blood-2019-125868

Published: 2019

Journal Articles

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Elliott P. Vichinsky, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD, Margaret Tonda, PharmD, Barbara Tong, PhD, Irene Agodoa, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Kenneth I. Ataga, MD

Blood (2019) 134 (Supplement_1): 2313.

https://doi.org/10.1182/blood-2019-129026

Published: 2019

Journal Articles

Progression of Central Nervous System Vasculopathy in Young Adults with Sickle Cell Anemia

Grace Champlin, MD, Scott Hwang, MD PhD, Guolian Kang, PhD, Juan Ding, PhD, Jeremie H. Estepp, MD, Kenneth I. Ataga, MD, Curtis L. Owens, MD, Justin Newman, MD, Lisa M. Jacola, PhD ABPP-CN, Allison A. King, MD MPH, PhD, Robert Davis, MD MPH, Winfred Wang, MD, Jane S. Hankins, MD MS

Blood (2019) 134 (Supplement_1): 2290.

https://doi.org/10.1182/blood-2019-129193

Published: 2019

Journal Articles

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Kenneth I. Ataga, MD, Santosh L. Saraf, MD, Vimal K. Derebail, MD, Claire C. Sharpe, Adlette Inati, MD, Jeffrey D. Lebensburger, DO, MSPH, Laurie DeBonnett, MD, Shirong Zhang, Pablo Bartolucci, MD PhD

Blood (2019) 134 (Supplement_1): 1018.

https://doi.org/10.1182/blood-2019-124823

Published: 2019

Journal Articles

Transition Continuity Promotes Long-Term Retention in Adult Care Among Young Adults with Sickle Cell Disease

Anjelica C. Saulsberry, BA, Kristen Howell, MPH, Joacy Mathias, MSc, Jerlym S. Porter, PhD MPH, Jason R. Hodges, PhD MA, Kenneth I. Ataga, MD, Sheila Anderson, RN, Vikki Nolan, MPH, DSc, Jane S. Hankins, MD MS

Blood (2019) 134 (Supplement_1): 4676.

https://doi.org/10.1182/blood-2019-129296

Published: 2019

Journal Articles

Opioid Analgesics Are Associated with Albuminuria in Adult Patients with Sickle Cell Anemia

Ashley Thrower, BS, Zhou Laura, Vimal K. Derebail, MD, David Wichlan, Ashley Smith, RN, Jianwen Cai, PhD, Kenneth I. Ataga, MD

Blood (2019) 134 (Supplement_1): 2308.

https://doi.org/10.1182/blood-2019-131368

Published: 2019

Journal Articles

Longitudinal Effect of Hydroxyurea Therapy on Left Ventricular Diastolic Function in Sickle Cell Anemia

Parul Rai, MD, Guolian Kang, PhD, Ronak Naik, MD, Jason Goldberg, MD, Xiwen Zhao, MSPH, Kenneth I. Ataga, MD, Vijaya Joshi, MD, Jane S. Hankins, MD MS

Blood (2019) 134 (Supplement_1): 1006.

https://doi.org/10.1182/blood-2019-130905

Published: 2019

Journal Articles

Rationale and Design of a Phase II Open-Label, Multicenter Study to Assess the Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Adult Patients with Sickle Cell Disease

Julie Kanter, MD, Brian Elliott, Denis Weber, Chiaki Tanaka, Fang Xiang, Kenneth I Ataga, MD

Blood (2017) 130 (Supplement 1): 4782.

https://doi.org/10.1182/blood.V130.Suppl_1.4782.4782

Published: 2017

Journal Articles

Urinary Specific Gravity Decreases over Time in Adult Sickle Cell Patients

Vimal K. Derebail, MD, Poulami Maitra, MS, Emily Jane Ciccone, MD, Ashley Thrower, BS, R Rosina Kilgore, MD, Jianwen Cai, PhD, Kenneth I Ataga, MD

Blood (2017) 130 (Supplement 1): 4783.

https://doi.org/10.1182/blood.V130.Suppl_1.4783.4783

Published: 2017

Journal Articles

Effect of Renin-Angiotensin-Aldosterone System Blocking Agents on Progression of Glomerulopathy in Sickle Cell Disease

Ashley Thrower, BS, Emily Jane Ciccone, MD, Poulami Maitra, MS, Jianwen Cai, PhD, Vimal K. Derebail, MD, Kenneth I Ataga, MD

Blood (2017) 130 (Supplement 1): 2246.

https://doi.org/10.1182/blood.V130.Suppl_1.2246.2246

Published: 2017

Journal Articles

Crizanlizumab 5.0 Mg/Kg Increased the Time to First on-Treatment Sickle Cell Pain Crisis: A Subgroup Analysis of the Phase II Sustain Study

Julie Kanter, MD, Abdullah Kutlar, MD, Darla Liles, Rodolfo Cançado, Andreas Bruederle, Michael Shi, MD PhD, Zewen Zhu, Kenneth I Ataga, MD

Blood (2017) 130 (Supplement 1): 613.

https://doi.org/10.1182/blood.V130.Suppl_1.613.613

Published: 2017

Journal Articles

Thrombospondin-1 Polymorphisms Are Associated with Chronic Kidney Disease in Sickle Cell Anemia

Seethal A. Jacob, MD, Enrico M. Novelli, MD MS, Jeffrey S. Isenberg, MD MPH, Melanie E. Garrett, MS, Yanxia Chu, MD, Karen L. Soldano, BS, Kenneth I. Ataga, MD, Marilyn J. Telen, MD, Allison E. Ashley-Koch, PhD, Yingze Zhang, PhD, Gregory J Kato, MD

Blood (2016) 128 (22): 2491.

https://doi.org/10.1182/blood.V128.22.2491.2491

Published: 2016

Journal Articles

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Julie Kanter, MD, Darla Liles, MD, Rodolfo Cancado, MD, PhD, João Friedrisch, MD PhD, Troy H. Guthrie, MD, Jennifer Knight-Madden, MBBS, PhD, Ofelia A. Alvarez, MD, Victor R. Gordeuk, MD, Sandra Gualandro, MD PhD, Marina Pereira Collela, MD PhD, Wally R. Smith, MD, Scott A. Rollins, PhD, Jonathan W. Stocker, PhD, Russell P. Rother, PhD

Blood (2016) 128 (22): 1.

https://doi.org/10.1182/blood.V128.22.1.1

Published: 2016

Journal Articles

Early Renal Disease in Children with Sickle Cell Disease from Malawi

Jonathan Brett Heimlich, Godwin Chipoka, MBBS, Graham Ellis, Laila Elsherif, PhD, Emeraghi David, Portia Kamthunzi, MBBS, Robert Krysiak, Yacinta Majawa, Pilirani Mafunga, Qingning Zhou, PhD, Jianwen Cai, PhD, Nigel S. Key, MB, ChB, FRCP,, Satish Gopal, Kenneth I. Ataga, MD

Blood (2016) 128 (22): 1316.

https://doi.org/10.1182/blood.V128.22.1316.1316

Published: 2016

Journal Articles

Progression of Chronic Kidney Disease in Sickle Cell Disease

Emily Ciccone, MD MHS, R. Rosina Kilgore, MD MPH, Qingning Zhou, PhD, Jianwen Cai, PhD, Vimal K. Derebail, MD MPH, Kenneth I. Ataga, MD

Blood (2016) 128 (22): 1323.

https://doi.org/10.1182/blood.V128.22.1323.1323

Published: 2016

Journal Articles

Alteration of the Structure and Dynamics of Venous Clot Formation in Human and Murine Sickle Cell Disease

Camille Faes, PhD, Anton Ilich, MD, Erica M Sparkenbaugh, PhD, Alisa S. Wolberg, PhD, Brian C. Cooley, PhD, Kenneth I. Ataga, MD, Nigel S. Key, MB, ChB, FRCP,, Rafal Pawlinski, PhD

Blood (2016) 128 (22): 2478.

https://doi.org/10.1182/blood.V128.22.2478.2478

Published: 2016

NARROW

The Effect of Crizanlizumab on the Number of Days Requiring Opioid Use for Management of Pain Associated with Vaso-Occlusive Crises in Patients with Sickle Cell Disease: Results from the Sustain Trial

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Progression of Central Nervous System Vasculopathy in Young Adults with Sickle Cell Anemia

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Transition Continuity Promotes Long-Term Retention in Adult Care Among Young Adults with Sickle Cell Disease

Opioid Analgesics Are Associated with Albuminuria in Adult Patients with Sickle Cell Anemia

Longitudinal Effect of Hydroxyurea Therapy on Left Ventricular Diastolic Function in Sickle Cell Anemia

Rationale and Design of a Phase II Open-Label, Multicenter Study to Assess the Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Adult Patients with Sickle Cell Disease

Urinary Specific Gravity Decreases over Time in Adult Sickle Cell Patients

Effect of Renin-Angiotensin-Aldosterone System Blocking Agents on Progression of Glomerulopathy in Sickle Cell Disease

Crizanlizumab 5.0 Mg/Kg Increased the Time to First on-Treatment Sickle Cell Pain Crisis: A Subgroup Analysis of the Phase II Sustain Study

Thrombospondin-1 Polymorphisms Are Associated with Chronic Kidney Disease in Sickle Cell Anemia

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Early Renal Disease in Children with Sickle Cell Disease from Malawi

Progression of Chronic Kidney Disease in Sickle Cell Disease

Alteration of the Structure and Dynamics of Venous Clot Formation in Human and Murine Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only